Broker describes Mesoblast limited as VERY STRONG buy

Could the share prices of Mesoblast limited (ASX:MSB) or Ademdus Ltd (ASX:AHZ) climb higher?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In the yin-yang world of biotechnology investing good news can result in strange effects as share prices fall despite companies' progressing further down the path to commercial success.

Indeed the scientists and investors at Mesoblast limited (ASX: MSB) might be cursing their yin-yang after the stock collapsed in half, despite the business raising around $80 million on the NASDAQ recently to help fund its commercial aspirations.

A NASDAQ listing was once thought of as a land of milk and honey for Australian tech startups, but Mesoblast has proven the opposite, although it does still have several brokers and an evangelical following of retail shareholders who still believe in the potential of the company's technology.

In fact broker Bell Potter is retaining a $4.50 price target on the stock, which suggests a 200% upside from here, or a tripling in value from today's price of $1.50.

Elsewhere (lesser known) Melbourne-based broker Lodge Partners Research has described it as a VERY STRONG BUY stating that the company now has US$136 million cash on its balance sheet to help fund it through many "value creating and potentially cash-generating events".

While analysts at US broker Ladenburg Thalmann have slapped a US$17.25 price target on the US scrip that currently sells for US$5.96, again suggesting a 200% upside or tripling in price for believers in the company's commercial potential.

For now it seems Mesoblast is facing a loss of investor confidence given its steep cash burn rate and calamitous Nasdaq-listing that has resulted in substantial dilution for existing holders. Moreover, questions remain over management's decision making in structuring a Nasdaq-listing that is unlikely to find itself in an MBA student's textbook on how to successfully raise capital.

Another biotech junior to have struggled recently due to a high cash burn and lack of revenues is Ademdus Ltd (ASX: AHZ). It has been attempting to sell its surgical heart patch named Cardiocel, although it has also been forced to repeatedly raise capital as sales did not hit the levels that investors perhaps initially expected.

Motley Fool contributor Tom Richardson has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. You can find Tom on Twitter @tommyr345 The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »